143 related articles for article (PubMed ID: 17551919)
1. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.
Leamon CP; Reddy JA; Vlahov IR; Kleindl PJ; Vetzel M; Westrick E
Bioconjug Chem; 2006; 17(5):1226-32. PubMed ID: 16984132
[TBL] [Abstract][Full Text] [Related]
3. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
[TBL] [Abstract][Full Text] [Related]
5. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F
Eur J Cancer; 2012 Sep; 48(13):2054-65. PubMed ID: 21937219
[TBL] [Abstract][Full Text] [Related]
7. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
[TBL] [Abstract][Full Text] [Related]
8. EC145: a novel targeted agent for adenocarcinoma of the lung.
Pribble P; Edelman MJ
Expert Opin Investig Drugs; 2012 May; 21(5):755-61. PubMed ID: 22462761
[TBL] [Abstract][Full Text] [Related]
9. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
10. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.
Li J; Sausville EA; Klein PJ; Morgenstern D; Leamon CP; Messmann RA; LoRusso P
J Clin Pharmacol; 2009 Dec; 49(12):1467-76. PubMed ID: 19837906
[TBL] [Abstract][Full Text] [Related]
12. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ; Harb WA; Pal SE; Boccia RV; Kraut MJ; Bonomi P; Conley BA; Rogers JS; Messmann RA; Garon EB
J Thorac Oncol; 2012 Oct; 7(10):1618-21. PubMed ID: 22982661
[TBL] [Abstract][Full Text] [Related]
13. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
14. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
15. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
Leamon CP; Reddy JA; Klein PJ; Vlahov IR; Dorton R; Bloomfield A; Nelson M; Westrick E; Parker N; Bruna K; Vetzel M; Gehrke M; Nicoson JS; Messmann RA; LoRusso PM; Sausville EA
J Pharmacol Exp Ther; 2011 Feb; 336(2):336-43. PubMed ID: 20978169
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting.
Müller C; Hohn A; Schubiger PA; Schibli R
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1007-16. PubMed ID: 16763819
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Dawson A; Dorton R; Vetzel M; Santhapuram HK; Wang Y
Mol Pharm; 2007; 4(5):659-67. PubMed ID: 17874843
[TBL] [Abstract][Full Text] [Related]
18. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
20. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
